Skip to content Skip to footer

The SAFE Banking Act passes the U.S House of Representatives

The SAFE Banking Act passes the U.S House of Representatives
Share this story
Share on twitter
Share on linkedin
Share on email

Eoin Keenan – Content & Communications Director

The Secure And Fair Enforcement Banking Act, SAFE, has recently been passed in the U.S. House of Representatives by a vote of 321 to 103. The SAFE Banking Act would grant the burgeoning cannabis industry access to basic banking and financial services, allowing institutions, insurance providers and investors the chance to safely and confidently trade with cannabis-based businesses.safe banking act

Whilst this is great news for those hoping to see legislative reform, how promising does it look for it to pass Senate?

At present, banks can work with cannabis businesses operating within the legal framework of their state; however, banks cannot offer the same range of services that would normally be available to businesses.

This means businesses operating within the cannabis industry must apply for temporary riders or resort to operating with cash, which is unsustainable and often results in business failure.

According to Neal Levine, CEO of the Cannabis Trade Federation, ‘the SAFE Banking Act will ensure state-legal cannabis businesses and their employees have access to the same basic banking and financial services (…) Allowing the cannabis industry to access banking services will reduce its reliance on cash and greatly improve safety for cannabis businesses, employees and consumers. It will also increase transparency and help law enforcement deter and detect illegal operations.’

Besides allowing businesses to operate in a safer and more transparent way, the SAFE Banking Act would also grant financial institutions the opportunity to invest without the danger of putting their institutions at risk of federal prosecution, something that would most certainly create an incentive for companies to invest in the industry.

Yet, whilst the executive director at the Marijuana Policy Project, Steve Hawkins, reminds us that this vote is an ‘indication that Congress is more willing than ever to support and take action on sensible cannabis policies’, the reality is that this bi-partisan legislation still doesn’t have enough support from the Republican-led Senate.

In fact, despite its bi-partisan design, the SAFE Banking Act is still far from being a Republican idea, with only 26 Republicans versus 180 Democrats signed on as co-sponsors, meaning that it could be an arduous process for this legislation to pass Mitch McConnell’s GOP-led Senate.

McConnell has been a staunch critic of the cannabis industry in the past, blocking cannabis banking reforms in 2018 and naming cannabis derivatives as ‘hemp’s illicit cousin which I choose not to embrace’. So, despite two-thirds of Americans saying they support the legalisation of cannabis, it seems unlikely that this Banking Act will pass through Senate.

If this wasn’t enough of a road-block, divisions are also present within the Democrats themselves, some, including the ACLU and the Center for American Progress arguing that this Banking Act isn’t comprehensive enough and doesn’t tackle the problem at its core.

Representative Maxine Waters, of the Democratic Party, instead urges for the House Judiciary Committee to pass the MORE Act, a bill to decriminalise and deschedule cannabis on the federal level saying that ‘it’s long overdue that Congress address the unjust criminalisation of marijuana use’.

Despite the historical passage of the SAFE Banking Act through the U.S House of Representatives, it seems unlikely that the bill will pass the Senate in the current political climate.

However, it is instrumental to not see this as a defeat – the traction and momentum generated by this Banking Act have positively impacted the industry as businesses operating in the cannabis industry have been given hope that the market will soon receive serious financial backing.

If you would like to understand more about the cannabis industry in North America, email our lead consultant, Barbara Pastori: Barbara@prohibitionpartners.com

Recent posts
May 19, 2022
Who Are Europe’s Medical Cannabis Patients?
May 5, 2022
Europe’s Pilot Trials Are a Tentative Step Towards Legal Medical Cannabis
April 28, 2022
The First Sales of Legal Adult-Use Cannabis in Europe Are Due in 2022
April 14, 2022
One Step Forward for CBD in the UK, but Questions Remain at Home and Abroad

Catch up on our newest articles that you might have missed

Untitled design (11)
May 19, 2022
Who Are Europe’s Medical Cannabis Patients?
The relatively close integration of medical cannabis into the European healthcare systems has contributed to a patient population and purchasing...
il-vagabiondo-Q7QCj-9-q3I-unsplash
May 5, 2022
Europe’s Pilot Trials Are a Tentative Step Towards Legal Medical Cannabis
Underlining the cautious approach Europe is taking to the liberalisation of medical cannabis are the pilot trial access schemes for...
vincent-ghilione-z54zUmYA9f8-unsplash
April 28, 2022
The First Sales of Legal Adult-Use Cannabis in Europe Are Due in 2022
Last week the first pilot project trial for the legalised sales of adult-use cannabis in Basel, Switzerland was approved by...
thomas-kelley--8iE9ykf3Us-unsplash
April 14, 2022
One Step Forward for CBD in the UK, but Questions Remain at Home and Abroad
The recent publishing of the list of CBD products with a valid Novel Foods application by the UK’s Food Safety...